| [May 26, 2016] |
 |
Global Type 2 Diabetes Report 2016 - Therapeutics Pipeline Review of 200+ Companies & Drug Profiles - Research and Markets
Research and Markets has announced the addition of the "Type
2 Diabetes - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic
development for Type 2 Diabetes , complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Type 2
Diabetes and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Key Topics Covered:
-
Introduction
-
Type 2 Diabetes Overview
-
Therapeutics Development
-
Pipeline Products for Type 2 Diabetes - Overview
-
Pipelne Products for Type 2 Diabetes - Comparative Analysis
-
Type 2 Diabetes - Therapeutics under Development by Companies
-
Type 2 Diabetes - Therapeutics under Investigation by
Universities/Institutes
-
Type 2 Diabetes Products Glance
-
Late Stage Products
-
Clinical Stage Products
-
Early Stage Products
-
Type 2 Diabetes - Products under Development by Companies
-
Type 2 Diabetes - Products under Investigation by
Universities/Institutes
-
Type 2 Diabetes - Companies Involved in Therapeutics Development
-
Addex Therapeutics Ltd
-
Adocia
-
Advinus Therapeutics Ltd.
-
Aegis Therapeutics, LLC
-
AFFiRiS AG
-
Alchemia Limited
-
Alize Pharma SAS (News - Alert)
-
AlphaMab Co., Ltd
-
Amarantus Bioscience Holdings, Inc.
-
Ambrx, Inc.
-
Amgen Inc.
-
Anchor Therapeutics, Inc.
-
AntriaBio, Inc.
-
Aphios Corporation
-
Araim Pharmaceuticals, Inc.
-
Arisaph Pharmaceuticals, Inc.
-
ArisGen SA
-
Array BioPharma Inc.
-
Artery Therapeutics, Inc.
-
Astellas Pharma Inc.
-
AstraZeneca Plc
-
AUS Bio Limited
-
Avaxia Biologics, Inc.
-
Bayer AG
-
Beta-Cell NV
-
Betagenon AB
-
Biocon Limited
-
Biodel Inc.
-
Biogenomics Limited
-
BioLingus AG
-
BioRestorative Therapies, Inc.
-
BioTherapeutics Inc.
-
BioTime, Inc.
-
Biscayne Pharmaceuticals, Inc.
-
Boehringer Ingelheim GmbH
For more information visit http://www.researchandmarkets.com/research/3qn64l/type_2_diabetes
View source version on businesswire.com: http://www.businesswire.com/news/home/20160526006201/en/
[ Back To TMCnet.com's Homepage ]
|
